The global Atopic Dermatitis Drugs market size is expected to be worth around US$ 8.41 billion by 2030, according to a new report by Vision Research Reports.
The global Atopic Dermatitis Drugs market size was valued at US$ 6.1 billion in 2020 and is anticipated to grow at a CAGR of 10.6% during forecast period 2021 to 2030.
Various factors such as emergence of novel therapeutics and growing uptake of targeted therapies are stimulating the growth of the market.
Eucrisa (Pfizer; crisaborole ointment) was approved by the U.S. FDA for treatment of atopic dermatitis (AD), in 2016. The drug is indicated for mild-to-moderate AD in patients who are two years or older, meeting a key therapeutics need of the market. Dupixent (Sanofi/Regeneron) was the first biologic to be launched in 2017 for management of AD. The drug is under clinical investigation for use in pediatric population.
Several promising candidates, especially biologics and small molecules, in pipeline are expected to alter the AD therapeutic landscape post launch. Nemolizumab is anticipated to be the first biologic (anti-IL-13) indicated for itching associated with atopic dermatitis. Tralokinumab, an IL-13 inhibitor, is under evaluation for safety and efficacy of treatment of moderate-to-severe AD.
Upcoming patent expiration of key products, such as LEO Pharma’s Protopic, Mylan/Valeant’s Elidel, and Bayer’s Desonate will result in generic penetration in therapeutic space. However, novel therapeutics, such as Eucrisa and Dupixent, are likely to gain traction over the forecast period and attain blockbuster status.
On the basis of drug class, the market is divided into corticosteroids, calcineurin inhibitors, phosphodiesterase4 (PDE4) inhibitors, biologics, and others. Corticosteroids have been the mainstay for AD treatment. Being the first-line therapy, this drug class is projected to maintain sizeable share in the market through 2022. Corticosteroids accounted for about 45.0% share in the market in 2016.
Calcineurin inhibitors are proven to increase the chances of nephrotoxicity and carcinogenesis. Non-specificity, toxic effects, and development of resistance to this therapeutic class are poised to stifle the growth of the segment and encourage switching to other targeted therapies.
Novel drug classes, such as PDE4 inhibitors and biologics, are expected to gain tremendous popularity over the forecast period on account of increasing adoption of targeted therapy as well as launch of pipeline candidates. Eucrisa (Pfizer; crisaborole ointment, 2.0%) is currently the only approved PDE4 inhibitor. It was approved by the FDA in 2016 for treatment of mild-to-moderate AD and is one of the few medicines indicated for pediatric usage.
Biologics are mostly prescribed for severe cases as second- or third-line of treatment, after the patient has shown insufficient or no response to prior therapies. Sanofi/Regeneron’s Dupixent is the only approved biologic for treatment of atopic dermatitis. Dupixent is currently under investigation for use in pediatric patients. Other than Dupixent, several biologics such as tralokinumab, nemolizumab, fezakinumab, and lebrikizumab are in the pipeline.
Based on route of administration, the AD drugs market can be segmented into topical, injectable, and oral. Topical products led the market and represented 70.0% of the market in 2016. Topical corticosteroids are the most widely prescribed medications for AD. They are often administered in combination with moisturizers or emollients for more effective results.
Dupixent’s launch, in 2017, marked arrival of injectables in AD therapeutic landscape. Although topicals are estimated to maintain their lead through 2022, injectables are likely to be the fastest growing segment during the forecast period. Antibiotics, antihistamines, and anti-inflammatory agents are generally administered by oral route.
Among the seven major markets, the U.S. dominated the global arena in 2016. The U.S. market is anticipated to register a healthy CAGR during the forecast period. Increasing incidence of atopic dermatitis, soaring treatment rate, and inflated drug prices are some of the key trends augmenting revenue generation in the country.
Japan is projected to register the highest CAGR during the same period. This growth of the region can be attributed to significant unmet clinical needs of patients, increasing spending on healthcare, and availability of effective treatment. Countries such as the U.K. and Spain are poised to hold prominent positions in the global arena throughout the forecast horizon.
Bayer, LEO Pharma, Mylan, Pfizer, and Sanofi. Mylan and LEO
Drug Class Outlook
Route of Administration Outlook
The Atopic Dermatitis Drugs market research report covers definition, classification, product classification, product application, development trend, product technology, competitive landscape, industrial chain structure, industry overview, national policy and planning analysis of the industry, the latest dynamic analysis, etc., and also includes major. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level.
The report provides size (in terms of volume and value) of Atopic Dermatitis Drugs market for the base year 2020 and the forecast between 2021 and 2030. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
This report focuses on the global Atopic Dermatitis Drugs market status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Atopic Dermatitis Drugs market development in United States, Europe and China.
It is pertinent to consider that in a volatile global economy, we haven’t just conducted Atopic Dermatitis Drugs market forecasts in terms of CAGR, but also studied the market based on key parameters, including Year-on-Year (Y-o-Y) growth, to comprehend the certainty of the market and to find and present the lucrative opportunities in market.
In terms of production side, this report researches the Atopic Dermatitis Drugs capacity, production, value, ex-factory price, growth rate, market share for major manufacturers, regions (or countries) and type.
In terms of consumption side, this report focuses on the consumption of Atopic Dermatitis Drugs by regions (countries) and application.
Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of production analysis, the authors of the report have provided reliable estimations and calculations for global revenue and volume by Type segment of the global Atopic Dermatitis Drugs market. These figures have been provided in terms of both revenue and volume for the period 2017 to 2030. Additionally, the report provides accurate figures for production by region in terms of revenue as well as volume for the same period. The report also includes production capacity statistics for the same period.
With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major Atopic Dermatitis Drugs market companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of Atopic Dermatitis Drugs market upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of market and consumption, major regions and Consumption, major Chinese producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The research in this report also includes product parameters, production process, cost structure, and data information classified by region, technology and application. Finally, the paper model new project SWOT analysis and investment feasibility study of the case model.
Overall, this is an in-depth research report specifically for the Atopic Dermatitis Drugs industry. The research center uses an objective and fair way to conduct an in-depth analysis of the development trend of the industry, providing support and evidence for customer competition analysis, development planning, and investment decision-making. In the course of operation, the project has received support and assistance from technicians and marketing personnel in various links of the industry chain.
The Atopic Dermatitis Drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to Atopic Dermatitis Drugs market.
Prominent players in the market are predicted to face tough competition from the new entrants. However, some of the key players are targeting to acquire the startup companies in order to maintain their dominance in the global market. For a detailed analysis of key companies, their strengths, weaknesses, threats, and opportunities are measured in the report by using industry-standard tools such as the SWOT analysis. Regional coverage of key companies is covered in the report to measure their dominance. Key manufacturers of Atopic Dermatitis Drugs market are focusing on introducing new products to meet the needs of the patrons. The feasibility of new products is also measured by using industry-standard tools.
Key companies are increasing their investments in research and development activities for the discovery of new products. There has also been a rise in the government funding for the introduction of new Atopic Dermatitis Drugs market. These factors have benefited the growth of the global market for Atopic Dermatitis Drugs. Going forward, key companies are predicted to benefit from the new product launches and the adoption of technological advancements. Technical advancements have benefited many industries and the global industry is not an exception.
New product launches and the expansion of already existing business are predicted to benefit the key players in maintaining their dominance in the global market for Atopic Dermatitis Drugs. The global market is segmented on the basis of region, application, en-users and product type. Based on region, the market is divided into North America, Europe, Asia-Pacific, Latin America and Middle East and Africa (MEA).
In this study, the years considered to estimate the market size of Atopic Dermatitis Drugs are as follows:
Reasons to Purchase this Report:
- Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
- Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
- Market value USD Million and volume Units Million data for each segment and sub-segment
- Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
- Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
This research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.
Market Size Estimation
Top-down and bottom-up approaches are used to estimate and validate the global market size for company, regional division, product type and application (end users).
The market estimations in this report are based on the selling price (excluding any discounts provided by the manufacturer, distributor, wholesaler or traders). Market share analysis, assigned to each of the segments and regions are achieved through product utilization rate and average selling price.
Major manufacturers & their revenues, percentage splits, market shares, growth rates and breakdowns of the product markets are determined through secondary sources and verified through the primary sources.
All possible factors that influence the markets included in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. The market size for top-level markets and sub-segments is normalized, and the effect of inflation, economic downturns, and regulatory & policy changes or others factors are accounted for in the market forecast. This data is combined and added with detailed inputs and analysis from Vision Research Reports and presented in this report.
Market Breakdown and Data Triangulation
After complete market engineering with calculations for market statistics; market size estimations; market forecasting; market breakdown; and data triangulation. Extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub-segments listed in this report.
Secondary Sources occupies approximately 25% of data sources, such as press releases, annual reports, Non-Profit organizations, industry associations, governmental agencies and customs data, and so on. This research study includes secondary sources; directories; databases such as Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), TRADING ECONOMICS, and avention; Investing News Network; statista; Federal Reserve Economic Data; annual reports; investor presentations; and SEC filings of companies.
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include product manufacturers (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the raw materials suppliers and producers, etc.
The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end users (product buyers), and related key executives from various key companies and organizations operating in the global market.
The study objectives of this report are:
To strategically profile the key players and comprehensively analyze their growth strategies.
Glioblastoma Multiforme Treatment Market (By Treatment: Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy, Immunotherapy; By Drug Class: Temozolomide, Bevacizumab, Lomustine, Carmustine Wafers, Others; By End-use: Hospitals, Clinics, Ambulatory Surgical Centers) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook 2021 – 2030Read more...
High Pressure Contrast Media Injectors Market (By Product: Injector Systems, Consumables; By Type: Single head injectors, Dual head injectors, Syringeless injectors; By Application: Interventional cardiology, Interventional radiology, Endovascular surgery, Interventional neuroradiology; By End-use: Hospitals, Diagnostic, Ambulatory Surgical Centers) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook 2021 – 2030Read more...
Veterinary Antimicrobial Susceptibility Testing Market (By Animal Type: Livestock Animals, Companion Animals; By Product: Disks & Plates, Culture Media, Accessories & Consumables, Automated AST Instruments; By End-use: Veterinary Reference Lab, Veterinary Research Institutes, Others) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook 2021 – 2030Read more...
Tendonitis Treatment Market (By Treatment: Therapy, Surgery; By Condition: Tennis Elbow, Golfer’s Elbow, Pitcher’s Elbow, Jumper’s Knee, Swimmer’s Shoulder, Achilles Tendonitis) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook 2021 – 2030Read more...
Infectious Disease Molecular Diagnostics Market (By Product: Instruments, Reagents, Services; By End-use: Hospitals, Clinics, Diagnostics Laboratories, Research Institutes; By Technology: Polymerase chain reaction, In Situ Hybridization, Isothermal Nucleic Acid Amplification Technology) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook 2021 – 2030Read more...